Finerenone and Empagliflozin in Type 2 Diabetes
Abstract
Cardiovascular disease and chronic kidney disease remain the leading causes of morbidity and mortality in patients with type 2 diabetes, even when conventional risk factors are well managed. Two drug classes have emerged over the past decade that reduce these risks through mechanisms that are largely independent of glucose lowering effect: sodium-glucose cotransporter 2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists. Empagliflozin demonstrated reductions in cardiovascular mortality, heart failure hospitalization, and kidney disease progression in the EMPA-REG OUTCOME trial and was subsequently shown to benefit patients with heart failure across the ejection fraction spectrum in the EMPEROR trials. Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist with phase III cardiorenal outcome data, reduced both cardiovascular and kidney composite endpoints in the FIDELIO-DKD and FIGARO-DKD trials, effects that were confirmed and strengthened in the pooled FIDELITY analysis of over 13,000 patients. These 2 agents target distinct pathophysiological pathways. Sodium-glucose cotransporter 2 inhibition acts primarily through hemodynamic and tubuloglomerular mechanisms, whereas finerenone addresses mineralocorticoid receptor driven inflammation and fibrosis in cardiac and renal tissue. The CONFIDENCE trial, published in 2025, was the first prospective study to test their combination; finerenone plus empagliflozin reduced urinary albumin.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.